No Data
No Data
San Noah Medicine (02257) has been removed from the Hang Seng Composite Small Cap Index and may be removed from the Hong Kong Stock Connect.
On August 16, the Hang Seng Index Company announced the latest quarterly review results. Among them, Shen Nuo Medicine (02257) was removed from the Hang Seng Composite Small Cap Index. The change will be implemented after the market closes on Friday, September 6, 2024, and will take effect from Monday, September 9, 2024.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Hong Kong stocks fluctuate | Sanofi-B (02257) rose more than 8% in intraday trading. The company has partnered with GRC to promote RNAi therapy in the field of cosmetic medicine.
Sanofi-B (02257) rose more than 8% during trading hours, and as of press time, rose 5.62%, reporting at HKD4.89 with a turnover of HKD 15.5463 million.
Shengnuo Medicine announced a partnership with Gore Range Capital to establish Sagesse Bio, promoting RNAi therapy in the field of aesthetic medicine.
On August 1, 2024, Hong Kong, Maryland, Germantown, and Suzhou /USA PR News/ -- Sirnaomics Ltd. ("the Company", stock code: 2257, together with its subsidiaries, collectively referred to as the "Group" or "Sirnaomics"), a leading biopharmaceutical company specializing in exploring and developing RNAi therapies, announced today the establishment of a joint venture, Sagesse Bio, Inc., with Gore Range Capital (Dallas, Texas, United States), for its novel RNAi therapy.
Hong Kong stocks in motion | Shengnuo Medicine-B (02257) rose by more than 11% at the opening. The company transferred patents to Sagesse Bio and obtained 60% of non-voting shares.
SanNuo Medicine-B (02257) opened more than 11%, as of press time, up 11.67%, at HKD 5.07, with a turnover of HKD 0.436 million.
Sanofi-B (02257.HK): Sirnaomics and Sagesse Bio signed a patent transfer and license agreement.
On August 1, Gelun Hui announced that the board of directors approved its wholly-owned subsidiary, USA Sirnaomics, to sign a patent transfer and license agreement with Sagesse Bio before the trading period on August 1, 2024. The content includes (i) transferring the rights of the transfer patent to Sagesse Bio for USA Sirnaomics; (ii) granting Sagesse Bio the exclusive global rights and licenses for the licensed patents used by USA Sirnaomics; and (iii)
No Data